Prescott Group Capital Management L.L.C. Buys Shares of 164,200 Affimed NV (AFMD)

Prescott Group Capital Management L.L.C. acquired a new stake in Affimed NV (NASDAQ:AFMD) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 164,200 shares of the biopharmaceutical company’s stock, valued at approximately $714,000. Prescott Group Capital Management L.L.C. owned 0.26% of Affimed at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in AFMD. FMR LLC purchased a new position in Affimed in the third quarter valued at about $5,552,000. EAM Global Investors LLC purchased a new position in Affimed in the third quarter valued at about $2,064,000. EAM Investors LLC purchased a new position in Affimed in the third quarter valued at about $656,000. Canada Pension Plan Investment Board purchased a new position in Affimed in the second quarter valued at about $165,000. Finally, Dimensional Fund Advisors LP raised its position in Affimed by 28.8% in the first quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 71,545 shares during the period. 44.27% of the stock is currently owned by institutional investors.

NASDAQ:AFMD opened at $4.60 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 3.66. Affimed NV has a 12 month low of $1.15 and a 12 month high of $7.35. The stock has a market capitalization of $275.14 million, a price-to-earnings ratio of -5.90 and a beta of 3.62.

Affimed (NASDAQ:AFMD) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The business had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.30 million. Affimed had a negative net margin of 2,124.72% and a negative return on equity of 82.22%. Equities research analysts anticipate that Affimed NV will post -0.72 EPS for the current fiscal year.

AFMD has been the topic of several research reports. ValuEngine lowered Affimed from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 13th. Zacks Investment Research raised Affimed from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research report on Tuesday, October 9th. Jefferies Financial Group raised Affimed from a “hold” rating to a “buy” rating and raised their price objective for the company from $1.80 to $4.00 in a research report on Tuesday, August 28th. SunTrust Banks cut their price objective on Affimed to $5.00 and set a “buy” rating on the stock in a research report on Thursday, October 11th. Finally, BidaskClub raised Affimed from a “sell” rating to a “hold” rating in a research report on Tuesday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Affimed currently has an average rating of “Buy” and an average target price of $4.81.

WARNING: “Prescott Group Capital Management L.L.C. Buys Shares of 164,200 Affimed NV (AFMD)” was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.wkrb13.com/2018/11/24/prescott-group-capital-management-l-l-c-buys-shares-of-164200-affimed-nv-afmd.html.

Affimed Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Story: What is Depreciation?

Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed NV (NASDAQ:AFMD).

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply